SPACEWALK (Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance) is a clinical trial for patients with ALK+ lung cancer.
Dr. Oxnard is the former PI of this study, now headed by Dr. Mark Awad
This study seeks to help researchers and clinicians to better understand this kind of cancer and to develop new future lung cancer treatments. Specifically, we are looking for genetic changes in the ALK gene that could help to understand why a cancer has developed drug resistance.
This clinical trial is for ALK-positive lung cancer patients who live in the United States.
The best way to determine eligibility is to fill out the form below. A member of our study team will get in touch with you to review the eligibility requirements and go over everything that will happen during the study.
Once eligibility is determined, a blood sample will be taken. You will be able to choose your own provider to collect the sample. We can also arrange for the sample to be collected at your home. Testing will be performed on the sample to look for genetic mutations in ALK and other genes and you and your doctor will receive these results, at no cost to you. We will then follow-up with you on your medical condition for a period of two years.
Participation in the study will not impact your current treatment regimen.
Feel free to contact us at 844-44-SPACE (844-447-7223) with any questions.
Please fill out the form below if you are interested in learning more about this clinical trial. Filling out the form does not require you to participate in the study and eligibility will be determined after meeting with a member of our study team.